GENITOURINARY CANCERS

泌尿生殖系统癌症

• 批准号: 8765172
• 负责人: William L. Carroll
• 金额: $ 1.68万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8765172
• 关键词: Advanced Development; Androgen Receptor; Area; Basic Science; Cancer Center Support Grant; Cancer Research Project; Clinical; Clinical Investigator; Clinical Research; Collaborations; Development; Diagnosis; Early treatment; Etiology; Funding; Genitourinary system; Goals; Image; Instruction; Malignant Neoplasms; Malignant neoplasm of prostate; Malignant neoplasm of urinary bladder; Molecular; Patients; Publications; Receptor Signaling; Research; Research Personnel; Risk; Scientist; Staging; Stratification; Translating; Translational Research; Urogenital Cancer; Work; cancer stem cell; carcinogenesis; cellular imaging; improved; member; novel; population based; programs; stem cell biology

PROJECT SUMMARY (See instructions): The Genitourinary Cancers Program is composed of 33 investigators (29 Full and 4 Associate members) from 13 Departments. The Program consists of a group of basic and clinical investigators collectively focused upon the study and treatment of GU malignancies. The specific aims of this Program are to: 1) Understandfundamental mechanisms that contribute to development and progression of prostate and bladder cancer; and 2) Support and advance the development of clinicians and research scientists working in a collaborative manner on GU cancers to establish novel basic, translational and clinical research programs. There are two major areas of research focus within the GU Cancer Program: prostate cancer and bladder cancer. The GU Program has developed funded research and clinical programs focused on androgen receptor (AR) signaling in prostate cancer, prostate cancer stem cells, imaging, diagnosis and focal therapy of early stage prostate cancers, as well as urothelial carcinogenesis. Utilizing these strengths, the current focus has expanded into imaging, focal therapy, molecular risk stratification, stem cell biology/etiology, and a population-based approach to racial disparity in prostate cancer. Drs. Michael Garabedian and Samir Taneja are the Co-Leaders for this Program. Total funding increased from $3,497,189 to $5,888,351 since the last competitive application. Membership has increased from 27 to 33. Publications for the period total 245, of which 26.9% are intra-programmatic, 12.2% are inter-programmatic, and 8.2% are both intra- and inter-programmatic collaborations.

项目摘要（请参阅说明）： 泌尿生殖器癌症计划由来自13个部门的33位调查人员（29名完整和4个同学）组成。该计划由一组基础和临床研究人员集体关注GU恶性肿瘤的研究和治疗。该计划的具体目的是：1）了解有助于前列腺和膀胱癌发展和进展的资产机制； 2）支持和推进临床医生和研究科学家的发展，以协作方式为GU癌症建立新颖的基本，转化和临床研究计划。 GU癌症计划中的研究重点有两个主要领域：前列腺癌和膀胱癌。 GU计划开发了针对雄激素受体（AR）信号传导的资助研究和临床计划 在前列腺癌，前列腺癌干细胞，早期前列腺癌的成像，诊断和局灶性治疗以及尿路上皮的致癌作用。利用这些优势，当前的重点已扩展到成像，局灶性疗法，分子风险分层，干细胞生物学/病因以及前列腺癌中种族差异的基于人群的方法。博士。 Michael Garabedian和Samir Taneja是该计划的共同领导者。自上次竞争激烈以来，总资金从3,497,189美元增加到5,888,351美元 应用。成员资格已从27个增加到33个。总计245期的出版物，其中26.9％为概括性，12.2％是程序间的，而8.2％是内部和程序间合作。